<DOC>
	<DOC>NCT00266695</DOC>
	<brief_summary>To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment. Patients must be off study drug for 6 to 18 months from completion of B7A-MC-MBCM before beginning B7A-MC-MBDV. Additional data will be gathered to determine the long-term safety and effect of ruboxistaurin on vision.</brief_summary>
	<brief_title>Treatment for Completers of the Study B7A-MC-MBCM</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ruboxistaurin</mesh_term>
	<criteria>Patients that completed Month 36 (Visit 15) of the study B7AMCMBCM, and the investigator believes he/she would benefit from ruboxistaurin treatment. Patients that discontinued from the study B7AMCMBCM and/or the investigator does not believe he/she would benefit from ruboxistaurin treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>